Clinical Trial: TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Anti-tumor Recurrence With Transarterial Chemoembolization (TACE) Plus Tegafur Versus TACE on Patients With Intrahepatic Cholangiocarcinoma After Curative Resection：

Brief Summary: The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) plus Tegafur with TACE alone in patients with intrahepatic cholangiocarcinoma after curative resection

Detailed Summary:
Sponsor: Eastern Hepatobiliary Surgery Hospital

Current Primary Outcome: Overall survival rates of each group [ Time Frame: 3 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Occurrence rate of recurrence of each group [ Time Frame: 3 years ]

Original Secondary Outcome: Same as current

Information By: Eastern Hepatobiliary Surgery Hospital

Dates:
Date Received: October 27, 2015
Date Started: December 2015
Date Completion: December 2017
Last Updated: March 30, 2016
Last Verified: March 2016